Use of epigallocatechin-3-gallate for immune regulation
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 6, 2012
app pub date -
Jun 3, 2011
filing date -
Jun 3, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The preset invention relates to a method for treating lupus erythematosus, particularly lupus nephritis, comprising administering a subject in need thereof a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully